

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
L5 and (antisense or ribozyme\$)	10

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
BM Technical Disclosure Bulletins

Search:

L6

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** Friday, June 13, 2003 [Printable Copy](#) [Create Case](#)**Set Name**
side by side**Query****Hit Count** **Set Name**
result set*DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=NO; OP=OR*

<u>L6</u>	L5 and (antisense or ribozyme\$)	10	<u>L6</u>
<u>L5</u>	L4 and reject\$	39	<u>L5</u>
<u>L4</u>	L3 and (vcam or elam or icam)	39	<u>L4</u>
<u>L3</u>	cornea\$ same allograft\$	326	<u>L3</u>
<u>L2</u>	L1 and (icam or elam or vcam)	10	<u>L2</u>
<u>L1</u>	cornea\$ same explant\$	103	<u>L1</u>

END OF SEARCH HISTORY

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
L4 and reject\$	39

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletin

Search:

L5

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** Friday, June 13, 2003 [Printable Copy](#) [Create Case](#)**Set Name**
side by side**Query****Hit Count** **Set Name**
result set*DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=NO; OP=OR*

<u>L5</u>	L4 and reject\$	39	<u>L5</u>
<u>L4</u>	L3 and (vcam or elam or icam)	39	<u>L4</u>
<u>L3</u>	cornea\$ same allograft\$	326	<u>L3</u>
<u>L2</u>	L1 and (icam or elam or vcam)	10	<u>L2</u>
<u>L1</u>	cornea\$ same explant\$	103	<u>L1</u>

END OF SEARCH HISTORY

File 5: Biosis Previews(R) 1963-2003/Jun W2

(c) 2003 BIOSIS

File 6: NTIS 1964-2003/Jun W3

(c) 2003 NTIS, Intl Cpyrht All Rights Res

***File 6: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.**

File 34: SciSearch(R) Cited Ref Sci 1990-2003/Jun W2

(c) 2003 Inst for Sci Info

File 40: Enviroline(R) 1975-2003/Jun

File 50: CAB Abstracts 1972-2003/May

(c) 2003 CAB International

***File 50: Truncating CC codes is recommended for full retrieval. See Help News50 for details.**

File 65: Inside Conferences 1993-2003/Jun W2

(c) 2003 BLDSC all rts. reserv

File 71: ELSEVIER BIOBASE 1994-2003/Jun W2

(c) 2003 Elsevier Science B.V.

File 73: EMBASE 1974-2003/Jun W2

(c) 2003 Elsevier Science B.V.

***File 73: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.**

File 94: JICST-EPlus 1985-2003/Jun W2

(c) 2003 Japan Science and Tech Corp(JST)

File 98: General Sci Abs/Full-Text 1984-2003/Apr

(c) 2003 The HW Wilson Co.

File 103: Energy SciTec 1974-2003/May B2

(c) 2003 Contains copyrighted material

***File 103: For access restrictions see Help Restrict.**

File 143: Biol. & Agric. Index 1983-2003/Apr

(c) 2003 The HW Wilson Co

File 144: Pascal 1973-2003/May W4

(c) 2003 INIST/CNRS

File 155: MEDLINE(R) 1966-2003/Jun W2

(c) format only 2003 The Dialog Corp.

***File 155: Medline has been reloaded and accession numbers have changed. Please see HELP NEWS 155.**

File 156: ToxFile 1965-2003/Jun W2

(c) format only 2003 The Dialog Corporation

***File 156: ToxFile has been reloaded. Accession numbers have changed. Please see HELP NEWS 156 for details.**

File 162: Global Health 1983-2003/May

(c) 2003 CAB International

***File 162: Effective May 1, name changes from CAB Health to Global Health.**

File 172: EMBASE Alert 2003/Jun W2

(c) 2003 Elsevier Science B.V.

File 305: Analytical Abstracts 1990-2003/May W3

(c) 2003 Royal Soc Chemistry

***File 305: Alert feature enhanced for multiple files, duplicate removal, customized scheduling. See HELP ALERT.**

File 369: New Scientist 1994-2003/Jun W1

(c) 2003 Reed Business Information Ltd.

File 370: Science 1996-1999/Jul W3

(c) 1999 AAAS

***File 370: This file is closed (no updates). Use File 47 for more current information.**

File 399: CA SEARCH(R) 1967-2003/UD=13824

(c) 2003 American Chemical Society

***File 399: Use is subject to the terms of your user/customer agreement. Alert feature enhanced for multiple files, etc. See HELP ALERT.**

File 434: SciSearch(R) Cited Ref Sci 1974-1989/Dec

(c) 1998 Inst for Sci Info

File 8: Ei Compendex(R) 1970-2003/Jun W1

(c) 2003 Elsevier Eng. Info. Inc.

***File 8: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.**

File 99: Wilson Appl. Sci & Tech Abs 1983-2003/Apr

(c) 2003 The HW Wilson Co.
File 135:NewsRx Weekly Reports 1995-2003/Jun W2
(c) 2003 NewsRx

***File 135: New newsletters are now added. See Help News135 for the complete list of newsletters.**

File 266:FEDRIP 2003/Apr
Comp & dist by NTIS, Intl Copyright All Rights Res
File 315:ChemEng & Biotec Abs 1970-2003/May
(c) 2003 DECHEMA
File 357:Derwent Biotech Res. 1982-2003/Jun W3
(c) 2003 Thomson Derwent & ISI

***File 357: File is now current. See HELP NEWS 357.**

Alert feature enhanced for multiple files, etc. See HELP ALERT.

File 358:Current BioTech Abs 1983-2003/May
(c) 2003 DECHEMA
File 35:Dissertation Abs Online 1861-2003/May
(c) 2003 ProQuest Info&Learning
File 48:SPORTDiscus 1962-2003/May
(c) 2003 Sport Information Resource Centre
File 91:MANTIS(TM) 1880-2002/Oct
2002 (c) Action Potential
File 149:TGG Health&Wellness DB(SM) 1976-2003/Jun W1
(c) 2003 The Gale Group
File 159:Cancerlit 1975-2002/Oct
(c) format only 2002 Dialog Corporation

***File 159: Cancerlit ceases updating with immediate effect.**

Please see HELP NEWS.

File 164:Allied & Complementary Medicine 1984-2003/Jun
(c) 2003 BLHCIS
File 442:AMA Journals 1982-2003/Nov B3
(c)2003 Amer Med Assn -FARS/DARS apply
File 444:New England Journal of Med. 1985-2003/Jun W2
(c) 2003 Mass. Med. Soc.
File 467:ExtraMED(tm) 2000/Dec
(c) 2001 Informania Ltd.

***File 467: For information about updating status please see Help News467.**

Set Items Description

--- ---

?s cornea? (s) explant?

232579 COPENA?

130403 EXPLANT?

S1 1177 COPENA? (S) EXPLANT?

?s s1 (s) (icam or elam or vcam)

1177 S1

71655 ICAM

4900 ELAM

24078 VCAM

S2 10 S1 (S) (ICAM OR ELAM OR VCAM)

?rd

...completed examining records

S3 4 RD (unique items)

?show files;ds;t/3,k/all

File 5:Biocsis Previews(R) 1969-2003/Jun W2

(c) 2003 BIOSIS

File 6:NTIS 1964-2003/Jun W3

(c) 2003 NTIS, Intl Cpyrgh All Rights Res

File 34:SciSearch(R) Cited Ref Sci 1990-2003/Jun W2

(c) 2003 Inst for Sci Info

File 40:Enviroline(R) 1975-2003/Jun

File 50:CAB Abstracts 1972-2003/May

(c) 2003 CAB International

File 65:Inside Conferences 1993-2003/Jun W2

(c) 2003 BLDSC all rts. reserv.

File 71:ELSEVIER BIOBASE 1994-2003/Jun W2

(c) 2003 Elsevier Science B.V.

File 73 EMBASE 1974-2003/Jun W2

(c) 2003 Elsevier Science B.V.
File 94 JICST-EPlus 1985-2003/Jun W2
(c) 2003 Japan Science and Tech Corp(JST)
File 98 General Sci Abs/Full-Text 1984-2003/Apr
(c) 2003 The HW Wilson Co.
File 103 Energy SciTec 1974-2003/May B2
(c) 2003 Contains copyrighted material
File 143 Biol. & Agric. Index 1983-2003/Apr
(c) 2003 The HW Wilson Co
File 144 Pascal 1973-2003/May W4
(c) 2003 INIST/CNRS
File 155 MEDLINE(R) 1966-2003/Jun W2
(c) format only 2003 The Dialog Corp.
File 156 ToxFile 1965-2003/Jun W2
(c) format only 2003 The Dialog Corporation
File 162 Global Health 1983-2003/May
(c) 2003 CAB International
File 172 EMBASE Alert 2003/Jun W2
(c) 2003 Elsevier Science B.V.
File 305 Analytical Abstracts 1980-2003/May W3
(c) 2003 Royal Soc Chemistry
File 369 New Scientist 1994-2003/Jun W1
(c) 2003 Reed Business Information Ltd.
File 370 Science 1996-1999/Jul W3
(c) 1999 AAAS
File 399 CA SEARCH(R) 1967-2003/UD=13824
(c) 2003 American Chemical Society
File 434 SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 1998 Inst for Sci Info
File 8 Ei Compendex(R) 1970-2003/Jun W1
(c) 2003 Elsevier Eng. Info. Inc.
File 99 Wilson Appl. Sci & Tech Abs 1983-2003/Apr
(c) 2003 The HW Wilson Co.
File 135 NewsRx Weekly Reports 1995-2003/Jun W2
(c) 2003 NewsRx
File 266 FEDRIP 2003/Apr
Comp & dist by NTIS, Intl Copyright All Rights Res
File 315 ChemEng & Biotech Abs 1970-2003/May
(c) 2003 DECHEMA
File 357 Derwent Biotech Res. _1982-2003/Jun W3
(c) 2003 Thomson Derwent & ISI
File 358 Current BioTech Abs 1983-2003/May
(c) 2003 DECHEMA
File 35 Dissertation Abs Online 1861-2003/May
(c) 2003 ProQuest Info&Learning
File 48 SPORTDiscus 1962-2003/May
(c) 2003 Sport Information Resource Centre
File 91 MANTIS(TM) 1880-2002/Oct
2002 (c) Action Potential
File 149 TGG Health&Wellness DB(SM) 1976-2003/Jun W1
(c) 2003 The Gale Group
File 159 Cancerlit 1975-2002/Oct
(c) format only 2002 Dialog Corporation
File 164 Allied & Complementary Medicine 1984-2003/Jun
(c) 2003 BLHCIS
File 442 AMA Journals 1982-2003/Nov B3
(c) 2003 Amer Med Assn -FARS/DARS apply
File 444 New England Journal of Med. 1985-2003/Jun W2
(c) 2003 Mass. Med. Soc.
File 467 ExtraMED(tm) 2000/Dec
(c) 2001 Informania Ltd.

Set	Items	Description
S1	1177	CORNEA? (S) EXFLANT?
S2	10	S1 (S) (ICAM OR ELAM OR VCAM)
S3	4	RD (unique items)

>>>KWIC option is not available in file(s): 399

3/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5-Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

14163665 BIOSIS NO.: 200300157694

Intercellular adhesion molecule-1 expression on human corneal epithelial outgrowth from limbal explant in culture.

AUTHOR: Iwata M(a); Fushimi N; Suzuki Y; Suzuki M; Sakimoto T; Sawa M
AUTHOR ADDRESS: (a)Department of Ophthalmology, Nihon University, School of Medicine, 30-1 Ohyaguchikami-machi, Itabashi-ku, Tokyo, 173-8610, Japan**
Japan

JOURNAL: British Journal of Ophthalmology 87 (2):p203-207 February 2003
2003

MEDIUM: print

ISSN: 0007-1161

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Aim: To investigate the relation between intercellular adhesion molecule (*ICAM*)-1 expression and cellular dynamics occurring concomitantly with epithelial cell movement. Methods: Outgrowing epithelial sheets of human *corneal* epithelial (HCE) cells from cultured limbal *explants* were examined by immunoperoxidase staining with anti-*ICAM*-1 monoclonal antibody. An adhesion assay was performed using the epithelial sheets of HCE cells and an Epstein-Barr virus (EBV) infected B cell lymphoma cell line (EBV+BJAB) expressing CD11a/CD18, a counter-receptor of *ICAM*-1. Also, the effect of calphostin C, a specific protein kinase C (PKC) inhibitor, on *ICAM*-1 expression on the outgrowing epithelial sheets of HCE cells was examined. Results: Strong positive staining for *ICAM*-1 was found predominantly on HCE cells in the marginal segment of the epithelial sheet, particularly on the cells at the leading edge. EBV+BJAB cells adhering to the HCE cells corresponded well to the area of *ICAM*-1 staining. Treatment of outgrowing epithelial sheets with calphostin C markedly decreased the *ICAM*-1 expression on the HCE cells. Conclusion: *ICAM*-1 is actively expressed on HCE cells in the marginal segment of the outgrowing epithelial sheets where there is active movement mediated through a PKC dependent mechanism, suggesting the role of *ICAM*-1 in epithelial cell motility such as the spreading and migration of cells.

3/3,K/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2003 Inst for Sci Info. All rts. reserv.

07614223 Genuine Article#: 178MF No. References: 0

Title: Dexamethasone inhibs cytokine induced *ICAM* and VEGF expression in human *corneal* *explants*

Author(s): Sims MG; Tsai SY; Lai CI; Bowen TA; Bouchard CS
Corporate Source: LOYOLA UNIV,MED CTR, PROGRAM NEUROSCI, DEPT CELL BIOL NEUROBIOL & ANAT/NEW ORLEANS//LA/70118; LOYOLA UNIV,MED CTR, DEPT OPHTHALMOL/NEW ORLEANS//LA/70118; CHICAGO COLL OSTEOPATH MED,/CHICAGO//IL/

Journal: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1999, V40, N4 (MAR 15), P36244-36244

ISSN: 0146-0404 Publication date: 19990315

Publisher: ASSOC RESEARCH VISION OPHTHALMOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998

Language: English Document Type: MEETING ABSTRACT

Title: Dexamethasone inhibs cytokine induced *ICAM* and VEGF expression in human *corneal* *explants*

3/3,K/3 (Item 1 from file: 399)

138332860 CA: 138(22)332860v PATENT

Antisense oligonucleotide targeting cell adhesion molecules for preserving corneal explants and preventing corneal allograft rejection

INVENTOR(AUTHOR): Bennett, C Frank; Mirabelli, Christopher K.

LOCATION: USA

ASSIGNEE: Isis Pharmaceuticals, Inc.

PATENT: PCT International ; WO 200332920 A2 DATE 20030424

APPLICATION: WO 2002US33236 (20021016) *US 982262 (20011018)

PAGES: 106 pp. CODEN PIXXD2 LANGUAGE English CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; ME; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; ME; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

3/3,K/4 (Item 2 from file: 399)

138331722 CA: 138(22)331722q PATENT

Oligonucleotide modulation of cell adhesion for preserving corneal explants and preventing corneal allograft rejection

INVENTOR(AUTHOR): Bennett, C. Frank; Mirabelli, Christopher

LOCATION: USA

PATENT: U.S. Pat. Appl. Publ. ; US 20030077565 A1 DATE: 20030424

APPLICATION: US 982262 (20011018) *US 7997 (19930121) *US 969151

(19930210) *US 63167 (19930517) *US 440740 (19950512) *US 128496 (19980803) *US 659288 (20000912)

PAGES: 58 pp., Cont.-in-part of U.S. Ser. No. 659,288, abandoned.

CODEN: USXXCO LANGUAGE: English CLASS: 435002000; A61K-048/00A; A01N-001/02B

?s s1 and (elam or vcam or icam) and (antisense or ribozyme?)

1177 S1

4900 ELAM

24078 VCAM

71655 ICAM

154052 ANTISENSE

31644 RIBOZYME?

S4 2 S1 AND (ELAM OR VCAM OR ICAM) AND (ANTISENSE OR RIBOZYME?)

?rd

...completed examining records

S5 2 FD (unique items)

?show files;ds;t/3,k/all

File 5: Biosis Previews(R) 1969-2003/Jun W2

(c) 2003 BIOSIS

File 6: NTIS 1964-2003/Jun W3

(c) 2003 NTIS, Intl Cpyrht All Rights Res

File 34: SciSearch(R) Cited Ref Sci 1990-2003/Jun W2

(c) 2003 Inst for Sci Info

File 40: Enviroline(R) 1975-2003/Jun

File 50: CAB Abstracts 1972-2003/May

(c) 2003 CAB International

File 65: Inside Conferences 1993-2003/Jun W2

(c) 2003 BLDSC all rts. reserv.

File 71: ELSEVIER BIOBASE 1994-2003/Jun W2

(c) 2003 Elsevier Science B.V.

File 73: EMBASE 1974-2003/Jun W2

(c) 2003 Elsevier Science B.V.

File 94:JICST-EPlus 1985-2003/Jun W2
(c) 2003 Japan Science and Tech Corp(JST)

File 98:General Sci Abs/Full-Text 1984-2003/Apr
(c) 2003 The HW Wilson Co.

File 103:Energy SciTec 1974-2003/May B2
(c) 2003 Contains copyrighted material

File 143:Biol. & Agric. Index 1983-2003/Apr
(c) 2003 The HW Wilson Co

File 144:Pascal 1973-2003/May W4
(c) 2003 INIST/CNRS

File 155:MEDLINE(R) 1966-2003/Jun W2
(c) format only 2003 The Dialog Corp.

File 156:ToxFile 1965-2003/Jun W2
(c) format only 2003 The Dialog Corporation

File 162:Global Health 1983-2003/May
(c) 2003 CAB International

File 172:EMBASE Alert 2003/Jun W2
(c) 2003 Elsevier Science B.V.

File 305:Analytical Abstracts 1980-2003/May W3
(c) 2003 Royal Soc Chemistry

File 369:New Scientist 1994-2003/Jun W1
(c) 2003 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3
(c) 1999 AAAS

File 399:CA SEARCH(R) 1967-2003/UD=13824
(c) 2003 American Chemical Society

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 1998 Inst for Sci Info

File 8:EI Compendex(R) 1970-2003/Jun W1
(c) 2003 Elsevier Eng. Info. Inc.

File 99:Wilson Appl. Sci & Tech Abs 1983-2003/Apr
(c) 2003 The HW Wilson Co.

File 135:NewsRx Weekly Reports 1995-2003/Jun W2
(c) 2003 NewsRx

File 266:FEDRIP 2003/Apr
Comp & dist by NTIS, Intl Copyright All Rights Res

File 315:ChemEng & Biotec Abs 1970-2003/May
(c) 2003 DECHEMA

File 357:Derwent Biotech Res. 1982-2003/Jun W3
(c) 2003 Thomson Derwent & ISI

File 358:Current BioTech Abs 1983-2003/May
(c) 2003 DECHEMA

File 35:Dissertation Abs Online 1861-2003/May
(c) 2003 ProQuest Info&Learning

File 48:SPORTDiscus 1962-2003/May
(c) 2003 Sport Information Resource Centre

File 91:MANTIS(TM) 1880-2002/Oct
2002 (c) Action Potential

File 149:TGG Health&Wellness DB(SM) 1976-2003/Jun W1
(c) 2003 The Gale Group

File 159:Cancerlit 1975-2002/Oct
(c) format only 2002 Dialog Corporation

File 164:Allied & Complementary Medicine 1984-2003/Jun
(c) 2003 BLHCIS

File 442:AMA Journals 1982-2003/Nov B3
(c) 2003 Amer Med Assn -FARS/DARS apply

File 444:New England Journal of Med. 1985-2003/Jun W2
(c) 2003 Mass. Med. Soc.

File 467:ExtraMED(tm) 2000/Dec
(c) 2001 Informania Ltd

Set	Items	Description
S1	1177	CORNEA? (S) EXPLANT?
S2	10	S1 (S) (ICAM OR ELAM OR VCAM)
S3	4	RD (unique items)
S4	2	S1 AND (ELAM OR VCAM OR ICAM) AND (ANTISENSE OR RIBOZYME?)
S5	2	RD (unique items)

>>>KWIC option is not available in file(s): 399

5/3,K/1 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

138332860 CA: 138(22)332860v PATENT

Antisense oligonucleotide targeting cell adhesion molecules for preserving corneal explants and preventing corneal allograft rejection

INVENTOR(AUTHOR): Bennett, C. Frank; Mirabelli, Christopher K.

LOCATION: USA

ASSIGNEE: Isis Pharmaceuticals, Inc.

PATENT: PCT International ; WO 200332920 A2 DATE: 20030424

APPLICATION: WO 2002US33236 (20021016) *US 982262 (20011018)

PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; ; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

5/3,K/2 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

138331722 CA: 138(22)331722q PATENT

Oligonucleotide modulation of cell adhesion for preserving corneal explants and preventing corneal allograft rejection

INVENTOR(AUTHOR): Bennett, C. Frank; Mirabelli, Christopher

LOCATION: USA

PATENT: U.S. Pat. Appl. Publ. ; US 20030077565 A1 DATE: 20030424

APPLICATION: US 982262 (20011018) *US 7997 (19930121) *US 969151

(19930210) *US 63167 (19930517) *US 440740 (19950512) *US 128496 (19980803)

*US 659288 (20000912)

PAGES: 58 pp., Cont.-in-part of U.S. Ser. No. 659,288, abandoned.

CODEN: USXXCO LANGUAGE: English CLASS: 435002000; A61K-048/00A;

A01N-001/02B

?s cornea? (s) allograft?

232579 CORNEA?

184996 ALLOGRAFT?

S6 3095 CORNEA? (S) ALLOGRAFT?

?s s6 and (vcam or elam or icam)

3095 S6

24078 VCAM

4900 ELAM

71655 ICAM

S7 94 S6 AND (VCAM OR ELAM OR ICAM)

?s s6 and (antisense or ribozyme?)

3095 S6

154052 ANTISENSE

31644 RIBOZYME?

S8 4 S6 AND (ANTISENSE OR RIBOZYME?)

?rd

...completed examining records

S9 4 RD (unique items)

?show files;ds;t/3,k/all

File 5:Biosis Previews(R) 1969-2003/Jun W2

(c) 2003 BIOSIS

File 6:NTIS 1964-2003/Jun W3

(c) 2003 NTIS, Intl Cpyrghrt All Rights Res

File 34:SciSearch(R) Cited Ref Sci 1990-2003/Jun W2

(c) 2003 Inst for Sci Info

File 40:EnviroLine(R) 1975-2003/Jun
 File 50:CAB Abstracts 1972-2003/May
 (c) 2003 CAB International
 File 65:Inside Conferences 1992-2003/Jun W2
 (c) 2003 BLDSC all rts. reserv.
 File 71:ELSEVIER BIOBASE 1994-2003/Jun W2
 (c) 2003 Elsevier Science B.V.
 File 73:EMBASE 1974-2003/Jun W2
 (c) 2003 Elsevier Science B.V.
 File 94 JICST-EPlus 1985-2003/Jun W2
 (c) 2003 Japan Science and Tech Corp(JST)
 File 98:General Sci Abs/Full-Text 1984-2003/Apr
 (c) 2003 The HW Wilson Co.
 File 103:Energy SciTec 1974-2003/May B2
 (c) 2003 Contains copyrighted material
 File 143:Biol. & Agric. Index 1983-2003/Apr
 (c) 2003 The HW Wilson Co
 File 144:Pascal 1973-2003/May W4
 (c) 2003 INIST/CNRS
 File 155:MEDLINE(R) 1966-2003/Jun W2
 (c) format only 2003 The Dialog Corp.
 File 156:ToxFile 1965-2003/Jun W2
 (c) format only 2003 The Dialog Corporation
 File 162:Global Health 1983-2003/May
 (c) 2003 CAB International
 File 172:EMBASE Alert 2003/Jun W2
 (c) 2003 Elsevier Science B.V.
 File 305:Analytical Abstracts 1980-2003/May W3
 (c) 2003 Royal Soc Chemistry
 File 369:New Scientist 1994-2003/Jun W1
 (c) 2003 Reed Business Information Ltd.
 File 370:Science 1996-1999/Jul W3
 (c) 1999 AAAS
 File 399:CA SEARCH(R) 1967-2003/UD=13824
 (c) 2003 American Chemical Society
 File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
 (c) 1998 Inst for Sci Info
 File 8:EI Compendex(R) 1970-2003/Jun W1
 (c) 2003 Elsevier Eng. Info. Inc.
 File 99:Wilson Appl. Sci & Tech Abs 1983-2003/Apr
 (c) 2003 The HW Wilson Co.
 File 135:NewsRx Weekly Reports 1995-2003/Jun W2
 (c) 2003 NewsRx
 File 266:FEDRIF 2003/Apr
 Comp & dist by NTIS, Intl Copyright All Rights Res
 File 315:ChemEng & Biotech Abs 1970-2003/May
 (c) 2003 DECHEMA
 File 357:Derwent Biotech Res. _1982-2003/Jun W3
 (c) 2003 Thomson Derwent & ISI
 File 358:Current BioTech Abs 1983-2003/May
 (c) 2003 DECHEMA
 File 35:Dissertation Abs Online 1861-2003/May
 (c) 2003 ProQuest Info&Learning
 File 48:SPORTDiscus 1962-2003/May
 (c) 2003 Sport Information Resource Centre
 File 91:MANTIS(TM) 1880-2002/Oct
 2002 (c) Action Potential
 File 149:TGG Health&Wellness DB(SM) 1976-2003/Jun W1
 (c) 2003 The Gale Group
 File 159:Cancerlit 1975-2002/Oct
 (c) format only 2003 Dialog Corporation
 File 164:Allied & Complementary Medicine 1984-2003/Jun
 (c) 2003 BLHCIS
 File 442:AMA Journals 1982-2003/Nov B3
 (c) 2003 Amer Med Assn -FARS/DARS apply
 File 444:New England Journal of Med. 1985-2003/Jun W2
 (c) 2003 Mass. Med. Soc.

Set	Items	Description
S1	1177	CORNEA? (S) EXPLANT?
S2	10	S1 (S) (ICAM OR ELAM OR VCAM)
S3	4	RD (unique items)
S4	2	S1 AND (ELAM OR VCAM OR ICAM) AND (ANTISENSE OR RIBOZYME?)
S5	2	RD (unique items)
S6	3095	CORNEA? (S) ALLOGRAFT?
S7	94	S6 AND (VCAM OR ELAM OR ICAM)
S8	4	S6 AND (ANTISENSE OR RIBOZYME?)
S9	4	RD (unique items)

>>>KWIC option is not available in file(s): 399

9/3,K/1 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

138332860 CA: 138(22)332860v PATENT
Antisense oligonucleotide targeting cell adhesion molecules for preserving corneal explants and preventing corneal allograft rejection
INVENTOR(AUTHOR): Bennett, C. Frank; Mirabelli, Christopher K.
LOCATION: USA
ASSIGNEE: Isis Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200332920 A2 DATE: 20030424
APPLICATION: WO 2002US33236 (20021016) *US 982262 (20011018)
PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; ; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

9/3,K/2 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

138331722 CA: 138(22)331722q PATENT
Oligonucleotide modulation of cell adhesion for preserving corneal explants and preventing corneal allograft rejection
INVENTOR(AUTHOR): Bennett, C. Frank; Mirabelli, Christopher
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20030077565 A1 DATE: 20030424
APPLICATION: US 982262 (20011018) *US 7997 (19930121) *US 969151 (19930210) *US 63167 (19930517) *US 440740 (19950512) *US 128496 (19980803) *US 659288 (20000912)
PAGES: 58 pp., Cont.-in-part of U.S. Ser. No. 659,288, abandoned.
CODEN: USXXCO LANGUAGE: English CLASS: 435002000; A61K-048/00A; A01N-001/02B

9/3,K/3 (Item 1 from file: 442)
DIALOG(R)File 442:AMA Journals
(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00115965
COPYRIGHT American Medical Association 2001

Corneal Dystrophies of Epithelial Genesis The Possible Therapeutic Use of Limbal Stem Cell Transplantation (ARTICLE)

... Retroviral transduction of the cultured cells could prevent production of the defective keratoepithelin by targeting the messenger RNA carrying the mutation. Such an approach using *ribozymes* has been used to target mutated rhodopsin in animal models of retinitis pigmentosa.^{29/} The proof of principle for this approach has been provided in...155-171.

19

Fenyon KR, Tseng SC. Limbal autograft transplantation for ocular surface disorders. Ophthalmology. 1989;96:709-722.

20.

Tsai RJ, Tseng SC. Human *allograft* limbal transplantation for *corneal* surface reconstruction. *Cornea*. 1994;13:389-400.

21.

Tsubota K, Satake Y, Ohyama M, et al. Surgical reconstruction of the ocular surface in advanced ocular cicatricial pemphigoid and...

... transplantation in patients with limbal stem cell deficiency. Br J Ophthalmol. 1999;83:414-419.

26.

Croasdale CR, Schwartz GS, Malling JV, Holland EJ. Keratolimbal *allograft* : recommendations for tissue procurement and preparation by eye banks, and standard surgical technique. *Cornea*. 1999;18:52-58.

27.

Pellegrini G, Golisano O, Paterna P, et al. Location and clonal analysis of stem cells and their differentiated progeny in...

... term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. Lancet. 1997;349:990-993.

29.

Lewin AS, Drenser KA, Hauswirth WW, et al. *Ribozyme* rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat Med. 1998;4:967-971.

30.

Bradshaw JJ, Obritsch WF...

9/3,K/4 (Item 2 from file: 442)

DIALOG(R)File 442:AMA Journals

(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00115712

COPYRIGHT American Medical Association 2000

Topical Soluble Tumor Necrosis Factor Receptor Type I Suppresses Ocular Chemokine Gene Expression and Rejection of Allogeneic Corneal Transplants (ARTICLE)

QIAN, YING; DEKARIS, IVA; YAMAGAMI, SATOFU; DANA, M. REZA
Archives of Ophthalmology
Dec, 2000; Laboratory Sciences: tzol666
LINE COUNT: 00573

... sTNFR-I- and vehicle only-treated groups was determined using a multiprobe ribonuclease protection assay. Results: Hosts treated with topical sTNFR-I experienced significantly enhanced *corneal* *allograft* survival compared with animals treated with vehicle alone (P=.01). Moreover, postoperative messenger RNA levels of RANTES and macrophage inflammatory protein-1B in sTNFR-I-treated eyes were substantially suppressed compared with vehicle-treated eyes. Vehicle-treated eyes bearing rejected *allografts* expressed higher levels of messenger RNA for both chemokines than control eyes bearing accepted *allografts*. Conclusions: Topical treatment with sTNFR-I promotes the acceptance of allogeneic corneal transplants and inhibits gene expression of 2 chemokines (RANTES and macrophage inflammatory protein-1B) associated with corneal graft

rejection. Clinical Relevance: Our findings support the feasibility of a topical anticytokine strategy as a means of reducing *corneal* *allograft* rejection without resorting to the use of potentially toxic immunosuppressive drugs. Arch Ophthalmol. 2000;118:1666-1671

DESPITE the overall success of *corneal* transplantation, immunologic rejection remains the principal threat to *allograft* longevity.^{1/} Although not all of the cellular and molecular components that mediate *corneal* graft rejection have been identified to date, there is increasing evidence that the proinflammatory cytokine tumor necrosis factor <unprintable> (TNF-<unprintable>) is involved in the...

... Based on these data, it has been proposed^{2,8,13/} that TNF-<unprintable> could serve as an appropriate target for therapeutic intervention in prevention of *corneal* *allograft* rejection. It has already been shown that administration of anti-TNF-<unprintable> therapy can be effective in treatment of immune-mediated diseases, including arthritis^{14-17...}

... can be associated with untoward adverse effects, in this study we investigated the effect of topical soluble TNFR-I (sTNFR-I) on the survival of *corneal* *allografts*. Soluble TNFR-I has been shown to profoundly suppress bioactivity of TNF-<unprintable> by binding free TNF-<unprintable> and preventing ligation of the membrane-bound receptors.^{17/}

Corneal *allograft* rejection is pathologically characterized by leukocytic infiltration into the graft stroma and adherence of mononuclear cells to the donor *corneal* endothelium.^{12/} Recruitment of immune and inflammatory cells to the target tissue, including *allografts*, has been associated with the function of specialized chemotactic cytokines known as chemokines.^{25/} Studies have shown that *corneal* transplant rejection is associated with profound up-regulation in ocular gene expression of CC (B) chemokines, including macrophage inflammatory protein-1 alpha, macrophage inflammatory protein...

... also interested in determining whether local suppression of TNF-<unprintable> activity by application of sTNFR-I could alter gene expression of the chemokines associated with *corneal* transplant rejection.

RESULTS

ORTHOTOPIC *CORNEAL* *ALLOGRAFT* SURVIVAL

A total of 50 corneas from B10.D2 mice were grafted orthotopically onto 50 BALB/c mice, of which 30 were randomized to receive...

... treated grafted eyes did not reveal any statistically significant differences.

COMMENT

In the present study, prophylactic administration of topical sTNFR-I enhanced the survival of *corneal* *allografts* disparate at multiple minor H antigens. These findings, coupled with the previous observation^{2/} that hosts with a genetic deficiency of TNFR-I exhibit a profound increase in the survival rate of minor H-mismatched *corneal* grafts, strongly confirm TNF-<unprintable> as an important mediator in the pathogenesis of *corneal* *allograft* rejection. We focused our attention on alloimmunity to minor antigens because it has been shown that disparity at the level of minor antigens provides a significantly more formidable immune barrier to *corneal* graft acceptance than disparity at major histocompatibility complex loci.^{29/} Accordingly, Sonoda and Streilein^{30/} showed that grafts disparate at multiple minor H antigens are rejected on the induction and expression of *corneal* alloimmune mechanisms remains incompletely understood. In the murine orthotopic *corneal* transplantation model, peak secretion of TNF-<unprintable> protein in allogeneic grafts is observed 1 to 2 weeks after surgery,^{8/} whereas graft rejection typically occurs...

... phase of alloimmunity is supported by previous data^{13/} from our laboratory showing that the migration of professional antigen-presenting cells (including Langerhans cells) into the *cornea* is largely mediated by TNF-<unprintable>. The critical role of antigen-presenting cell migration in indirect sensitization of T cells to *corneal* transplants^{31,32/} is emphasized by data^{33/} showing that suppression of Langerhans cell trafficking into *corneal* grafts can prevent host sensitization to the

transplants. Accordingly, we propose that local neutralization of TNF-~~unprintable~~ activity by application of sTNFR-I imposes its beneficial effect on *allograft* survival, at least in part, by inhibiting leukocyte recruitment in the early postoperative period.

As shown previously,^{13/} TNF-~~unprintable~~ need not effect its chemoattractant.

... chemokine mRNA in grafted hosts treated with sTNFR-I and vehicle alone. Consistent with previous findings^{26/} in major histocompatibility complex and minor H fully mismatched *corneal* transplantation, increased gene expression of RANTES and MIP1B is associated with rejection of minor H-disparate *corneal* grafts. More important, our results clearly show that sTNFR-I therapy applied after *corneal* transplantation significantly down-regulates local gene expression of RANTES and MIP1B. These ligands, by virtue of binding to the widely expressed CCR1 and CCR5 receptors...

... as critical chemoattractants for antigen-presenting cells and activated CD4⁺/T cells.^{6,7,37,38/} Preliminary data from our laboratory in nontransplant models of *corneal* inflammation show a significant suppression of *corneal* dendritic cell migration in response to *corneal* injury after treatment with sTNFR-I (unpublished observations). Our present data demonstrating that sTNFR-I treatment can suppress expression of RANTES and MIP1B below that for accepted untreated *corneas* suggest that the depressed level of chemokine expression is not simply secondary to suppression of the rejection process but rather a mechanism by which sTNFR-I can mediate its beneficial effect on *allograft* survival. Taken together, these data support our hypothesis that sTNFR-I can down-modulate the induction and expression phases of alloimmunity by suppressing leukocyte recruitment...this represents the first study providing evidence for local anti-TNF strategies, using the novel method of topically administering sTNFR-I, for effective prevention of *corneal* *allograft* rejection. Various forms of recombinant sTNFR-I, including monomeric 4 domain, monomeric 2.6 domain, and 30-kd polyethylene glycol-linked 2.6 domain molecules...

... surface that is also well tolerated because of its biophysical properties and hence can increase the availability of pharmacotherapeutic agents to the ocular surface and *cornea*.^{41,42/}

Currently available preventive and therapeutic regimens for corneal transplant rejection are associated with significant complications.^{43/} Hence, it is desirable to devise intervention...

...Interferon Cytokine Res. 1999;19:661-669.

9.

Torres PF, DeVos AF, van der Gaag R, Martins B, Kijlstra A. Cytokine mRNA expression during experimental *corneal* *allograft* rejection. Exp Eye Res. 1996;63:453-461.

10.

Pleyer U, Milani JK, Ruckert D, Rieck P, Mondino BJ. Determinations of serum tumor necrosis factor alpha in *corneal* *allografts*. Ocul Immunol Inflamm. 1997;5:149-155.

11.

Sano Y, Osawa H, Sotozono C, Kinoshita S. Cytokine expression during orthotopic *corneal* *allograft* rejection in mice. Invest Ophthalmol Vis Sci. 1998;39:1953-1957.

12.

Larkin DF, Calder VL, Lightman SL. Identification and characterization of cells infiltrating the graft and aqueous humour in rat *corneal* *allograft* rejection. Clin Exp Immunol. 1997;107:381-391.

13.

Dekaris I, Zhu S, Dana MR. TNF-~~unprintable~~ regulates corneal Langerhans cell migration. J Immunol 1999...Wood KJ. Indirect presentation of MHC antigens in transplantation. Immunol Today. 1994;15:32-38.

32.

Sano Y, Ksander BR, Streilein JW. Fate of orthotopic *corneal* *allografts* in eyes that cannot support anterior chamber-associated immune deviation induction. Invest Ophthalmol Vis Sci. 1995;36:2176-2185.

... cyclosporin A: background, immunology, and pharmacology. Cornea. 1990;9:184-195.

44.

Ma D, Mellon J, Niederkorn JY. Oral immunisation as a strategy for enhancing *corneal* *allograft* survival. Br J Ophthalmol. 1997;81:778-784.

45.

Van der Veen G, Broersma L, Dijkstra CD, Van Rooijen N, Van Rij G, Van der Gaag R. Prevention of *corneal* *allograft* rejection in rats treated with subconjunctival injections of liposomes containing dichloromethylene diphosphonate. Invest Ophthalmol Vis Sci. 1994;35:3505-3515.

46.

Yamada J, Yoshida M, Taylor AW, Streilein JW. Mice with Th2-biased immune systems accept orthotopic *corneal* *allografts* placed in 'high risk' eyes. J Immunol. 1999;162:5247-5255.

47.

He Y, Mellon J, Apte R, Niederkorn JY. Effect of LFA-1 and ICAM-1 antibody treatment on murine *corneal* *allograft* survival. Invest Ophthalmol Vis Sci. 1994;35:3218-3225.

48.

Dana MR, Yamada J, Streilein JW. Topical interleukin 1 receptor antagonist promotes corneal transplant survival. Transplantation. 1997;63:1501-1507.

49.

Zhang EP, Pohl T, Bulfone-Paus S, Wachtlin J, Kunzendorf U, Hoffmann F. Prolongation of *corneal* *allograft* survival by an interleukin-2-immunoglobulin fusion protein in mice. Graefes Arch Clin Exp Ophthalmol. 1998;236:486-492.

50.

Yamagami S, Tsuru T, Ohkawa T, Endo H, Isobe M. Suppression of *allograft* rejection with anti-alphabeta T cell receptor antibody in rat *corneal* transplantation. Transplantation. 1999;67:600-604.

MATERIALS AND METHODS

ANIMALS

Six- to 8-week-old male BALB/c mice (Taconic Farms Inc, Germantown, NY) and... a multiprobe ribonuclease protection assay system (PharMingen, San Diego, Calif) as recommended by the supplier. Briefly, a mixture of [unprintable]-/32/P]uridine triphosphate-labeled *antisense* riboprobes was generated from the chemokine template set mCK-5 (PharMingen). Fifteen micrograms of total RNA was used in each sample. Total RNA was hybridized overnight at 56 degreesC with 300 pg of the /32/P *antisense* riboprobe mixture. Nuclease-protected RNA fragments were purified by ethanol precipitation. After purification, the samples were resolved on 5% polyacrylamide sequencing gels. The gels were...

?